Acceleron

This page shows the latest Acceleron news and features for those working in and with pharma, biotech and healthcare.

BMS’s Reblozyl meets primary endpoint in myelodysplastic syndromes phase 3 trial

Reblozyl is being developed and commercialised through a global collaboration with Merck following Merck’s acquisition of Acceleron Pharma in November 2021.

Latest news

Merck’s $11.5bn acquisition of Acceleron delayed

The withdrawal of its notification was prompted by a campaign from hedge fund, Avoro Capital Advisors, which owns a 7% stake in Acceleron. ... The fund stressed that Merck would be a 'great partner' for Acceleron, so the problem was 'not the fit', rather
Merck to acquire Acceleron in a deal worth around $11.5bn

driven by an unwavering dedication to delivering life-changing medicines for patients,” said Habib Dable, chief executive officer and president, Acceleron. ... Under the terms of the acquisition agreement, Merck’s acquisition subsidiary will be
Mysterious big pharma company eyes US biotech Acceleron

Speculation is running high that a major pharma company will make a move on Massachusetts-based pulmonary and haematology biotech Acceleron this week. ... Sales of Reblozyl have been growing since its launch in 2019 – BMS reported $240m in the first
BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients

Along with our partners at Acceleron, we are committed to advancing our clinical programme for Reblozyl for patients living with anaemia-associated blood disorders,” he added. ... We are very encouraged by the magnitude of improvement seen
Acceleron rockets on positive mid-stage pulmonary arterial hypertension data

We’re thrilled to report such positive top-line results from the PULSAR trial,” said Habib Dable, president and chief executive officer of Acceleron. ... Acceleron is due to present a detailed review of the top-line results from PULSAR trial at an

More from news
Approximately 6 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Bluebird Bio: on the cusp of a gene therapy revolution

B38M. There are other challengers in the field – Celgene and Acceleron look set to file their own beta thalassemia product, which looks set for filing after encouraging phase III data was

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

New hires at Bristol-Myers Squibb, Acceleron and FerGene

Acceleron . Acceleron Pharma has poached Jay Backstrom (pictured right) from Celgene, where he worked as chief medical officer. ... He has been appointed to the newly created role of head of research and development at the company, and brings almost